Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
Standard
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. / Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina; Liu, Lingfeng Steven; Balakrishnan, Ashwini; Salter, Alex; Hudecek, Michael; Maloney, David G; Turtle, Cameron J.
In: CANCER J, Vol. 20, No. 2, 29.03.2014, p. 141-4.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
AU - Riddell, Stanley R
AU - Sommermeyer, Daniel
AU - Berger, Carolina
AU - Liu, Lingfeng Steven
AU - Balakrishnan, Ashwini
AU - Salter, Alex
AU - Hudecek, Michael
AU - Maloney, David G
AU - Turtle, Cameron J
PY - 2014/3/29
Y1 - 2014/3/29
N2 - The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.
AB - The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.
KW - Antigens, CD19/immunology
KW - B-Lymphocytes/immunology
KW - CD8-Positive T-Lymphocytes/immunology
KW - Humans
KW - Immunotherapy, Adoptive
KW - Lymphoma, B-Cell/immunology
KW - Receptors, Antigen, T-Cell/immunology
U2 - 10.1097/PPO.0000000000000036
DO - 10.1097/PPO.0000000000000036
M3 - SCORING: Review article
C2 - 24667960
VL - 20
SP - 141
EP - 144
JO - CANCER J
JF - CANCER J
SN - 1528-9117
IS - 2
ER -